AstraZeneca (AZN) News Today → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free AZN Stock Alerts $80.02 -0.81 (-1.00%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 1:36 AM | americanbankingnews.comAstraZeneca PLC (NASDAQ:AZN) Given Average Rating of "Moderate Buy" by BrokeragesJune 9 at 9:16 AM | marketbeat.comVestal Point Capital LP Purchases New Shares in AstraZeneca PLC (NASDAQ:AZN)Vestal Point Capital LP purchased a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 250,000 shares of the company's stock, valued at approximately $16,838,000. AstraZeJune 8 at 9:33 AM | marketbeat.comAstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Envestnet Asset Management Inc.Envestnet Asset Management Inc. boosted its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 5.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,726,180 shares of the cJune 7 at 5:25 PM | marketbeat.comAstraZeneca PLC (NASDAQ:AZN) Shares Bought by Epoch Investment Partners Inc.Epoch Investment Partners Inc. raised its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 3.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,819,965 shares of the company's stock after acJune 7 at 4:13 PM | investorplace.comThe No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right NowJune 7 at 10:59 AM | cnbc.comHealthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins bigJune 6, 2024 | marketbeat.com1832 Asset Management L.P. Buys 330,310 Shares of AstraZeneca PLC (NASDAQ:AZN)1832 Asset Management L.P. lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 1,598.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 350,978 shares of the company's stock after purchasing an adJune 5, 2024 | marketbeat.comRafferty Asset Management LLC Raises Holdings in AstraZeneca PLC (NASDAQ:AZN)Rafferty Asset Management LLC boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 35.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 166,959 shares of the company's stock after acquiring an additioJune 5, 2024 | businesswire.comNucleus RadioPharma Secures Series A Extension Funding with AstraZeneca InvestmentJune 4, 2024 | cnbc.comWhy CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030June 4, 2024 | marketbeat.comCIBC Asset Management Inc Buys 11,892 Shares of AstraZeneca PLC (NASDAQ:AZN)CIBC Asset Management Inc raised its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 5.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 223,618 shares of the company's stock after purchasinJune 4, 2024 | prnewswire.comAbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024June 3, 2024 | marketbeat.comCIBC Private Wealth Group LLC Boosts Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)CIBC Private Wealth Group LLC grew its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 9.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,424,914 shares of the company's stock after buying an additional 889June 3, 2024 | marketbeat.comAstraZeneca (NASDAQ:AZN) Reaches New 52-Week High at $79.47AstraZeneca (NASDAQ:AZN) Sets New 12-Month High at $79.47June 3, 2024 | fool.comThe Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.June 2, 2024 | marketbeat.comCloverfields Capital Group LP Acquires 11,877 Shares of AstraZeneca PLC (NASDAQ:AZN)Cloverfields Capital Group LP grew its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 46.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,268 shares of the company's stock after buying an addJune 2, 2024 | businesswire.comTAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trialJune 2, 2024 | businesswire.comIMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placeboJune 2, 2024 | businesswire.comENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapyJune 2, 2024 | businesswire.comENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine TherapyJune 2, 2024 | fool.com3 No-Brainer Stocks to Buy in JuneJune 1, 2024 | marketbeat.comEagle Asset Management Inc. Sells 597,005 Shares of AstraZeneca PLC (NASDAQ:AZN)Eagle Asset Management Inc. trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 30.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,347,965 shares of the company's stock afterJune 1, 2024 | marketbeat.comShort Interest in AstraZeneca PLC (NASDAQ:AZN) Declines By 10.1%AstraZeneca PLC (NASDAQ:AZN - Get Free Report) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 7,670,000 shares, a decrease of 10.1% from the April 30th total of 8,530,000 shares. Based on an average daily trading volume, of 5,310,000 shares, the short-interest ratio is currently 1.4 days.June 1, 2024 | americanbankingnews.comAstraZeneca (NASDAQ:AZN) PT Raised to $85.00 at ArgusMay 31, 2024 | marketbeat.comAstraZeneca PLC (NASDAQ:AZN) Position Boosted by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 19.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 147,251 shares of the company's stockMay 30, 2024 | marketbeat.comSanders Capital LLC Has $988.97 Million Position in AstraZeneca PLC (NASDAQ:AZN)Sanders Capital LLC increased its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 39.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,684,066 shares of the company's stoMay 30, 2024 | marketbeat.comAstraZeneca (NASDAQ:AZN) Price Target Increased to $85.00 by Analysts at ArgusArgus boosted their price target on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a "buy" rating in a research note on Thursday.May 30, 2024 | fool.comThis Pharma Stock Is Poised to Keep Outperforming the S&P 500May 30, 2024 | prnewswire.comCompugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating RilvegostomigMay 29, 2024 | marketbeat.com26,252 Shares in AstraZeneca PLC (NASDAQ:AZN) Acquired by Catalytic Wealth RIA LLCCatalytic Wealth RIA LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 26,252 shares of the company's stock, valued at approMay 29, 2024 | msn.comFusion shareholders give green light to AstraZeneca acquisitionMay 29, 2024 | msn.comAmgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's DrugMay 29, 2024 | fool.comAstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the StockMay 29, 2024 | fool.comAstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?May 28, 2024 | reuters.comUS FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatmentMay 28, 2024 | msn.comWhy Is AstraZeneca Stock Trading Lower On Tuesday?May 27, 2024 | msn.comAstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: ReportMay 27, 2024 | marketbeat.comUS Bancorp DE Has $12.57 Million Stake in AstraZeneca PLC (NASDAQ:AZN)US Bancorp DE raised its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 20.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 186,629 shares of the company's stock after purchasing an additional 31,252 shares dMay 27, 2024 | markets.businessinsider.comAZN:Datopotamab Deruxtecan Shows Favorable Survival Results, Falls Short Of Statistical SignificanceMay 27, 2024 | businesswire.comDatopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trialMay 27, 2024 | businesswire.comDatopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 TrialMay 25, 2024 | marketbeat.comOrion Portfolio Solutions LLC Raises Stake in AstraZeneca PLC (NASDAQ:AZN)Orion Portfolio Solutions LLC raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 10.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 140,712 shares oMay 25, 2024 | marketbeat.comAstraZeneca PLC (NASDAQ:AZN) is Primecap Management Co. CA's 10th Largest PositionPrimecap Management Co. CA cut its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 42,987,075 shares of the company's stock after selling 902,2May 24, 2024 | finance.yahoo.comHere's Why We Think AstraZeneca (LON:AZN) Is Well Worth WatchingMay 23, 2024 | marketbeat.comAssetmark Inc. Buys 15,642 Shares of AstraZeneca PLC (NASDAQ:AZN)Assetmark Inc. boosted its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 11.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 154,906 shares of the company's stock after purchasing an additional 1May 23, 2024 | businesswire.comAstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)May 22, 2024 | prnewswire.comNona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted TherapiesMay 22, 2024 | benzinga.comHere's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 YearsMay 22, 2024 | marketbeat.comWells Fargo & Company MN Grows Holdings in AstraZeneca PLC (NASDAQ:AZN)Wells Fargo & Company MN raised its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 7.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,045,394 shares of the company's stockMay 22, 2024 | msn.comAstra Aims to Almost Double Sales to $80 Billion by 2030 Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address It's time to ween off Chinese lithium! (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely Learn how this American company is leading the lithium-ion revolution AZN Media Mentions By Week AZN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZN News Sentiment▼1.180.76▲Average Medical News Sentiment AZN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZN Articles This Week▼1415▲AZN Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Eli Lilly and Company News Novo Nordisk A/S News Johnson & Johnson News Merck & Co., Inc. News AbbVie News Novartis News Abbott Laboratories News Pfizer News Vertex Pharmaceuticals News Sanofi News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AZN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...Porter & Company | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredTime is Running Out - June 25th Deadline Approaching!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | Sponsored